[Immunosuppression: a paraneoplastic syndrome].
D000230:Adenocarcinoma / Q000276:immunology; D000328:Adult; D001943:Breast Neoplasms / Q000276:immunology; D001984:Bronchial Neoplasms / Q000276:immunology; D046508:Culture Techniques; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D005452:Fluoresceins; D006689:Hodgkin Disease / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D007109:Immunity; D007111:Immunity, Cellular; D007165:Immunosuppression Therapy; D007945:Leukemia, Lymphoid / Q000276:immunology*; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D008545:Melanoma / Q000276:immunology; D009369:Neoplasms / Q000276:immunology* / Q000601:surgery; D010051:Ovarian Neoplasms / Q000276:immunology; D010190:Pancreatic Neoplasms / Q000276:immunology; D010954:Plasmacytoma / Q000276:immunology; D013274:Stomach Neoplasms / Q000276:immunology; D014374:Tuberculin Test; D014750:Vincristine / Q000627:therapeutic use
D005452:Fluoresceins; D014750:Vincristine; D003520:Cyclophosphamide
Immunosuppression: ein paraneoplastisches Syndrom.